David J. Arthur - Nov 3, 2022 Form 4/A - Amendment Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Stock symbol
SLRX
Transactions as of
Nov 3, 2022
Transactions value $
$17,340
Form type
4/A - Amendment
Date filed
11/8/2022, 04:42 PM
Date Of Original Report
Nov 7, 2022
Previous filing
May 31, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Award $17.3K +10K +90.69% $1.73 21K Nov 3, 2022 Direct F1
holding SLRX Common Stock 564 Nov 3, 2022 By son
holding SLRX Common Stock 552 Nov 3, 2022 By daughter
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c)